We provide a validated and rapid protocol for the solubilization of amyloid b-peptide (Ab). This procedure involves sequential solubilization using structure-breaking organic solvents hexafluoroisopropanol and DMSO followed by column purification. The low solubility and tendency of Ab to aggregate considerably impede the in vitro handling and biophysical or biological investigation of Ab, despite the interest in this peptide because of its implication in Alzheimer's disease. The main advantage of the proposed protocol over others is that it results in standardized aggregate-free Ab peptide samples that are biocompatible for cell culture studies and yield reproducible aggregation kinetics and cytotoxicities. This three-step protocol also enables the co-solubilization of the longer Ab42 variant with Ab40 in ratios relevant to Alzheimer's disease.
Introduction
The importance of protein aggregation has become increasingly clear in the last decades with the discovery of a link between this phenomenon and a number of human diseases, including scrapie (Prusiner et al., 1983) , familial amyloidosis (Costa et al., 1978) and Parkinson's disease (Spillantini et al., 1997) . Among the proteins identified in amyloid plaques, amyloid b (Ab) peptides are special because they constitute what could be considered as the prototype of an intrinsically unstructured sequence with an unusually high amphipathic character. Also, they are directly implicated in Alzheimer's disease, one of the emerging threats of modern society. Ab peptides are generated from amyloid precursor protein as a result of sequential b-secretase and g-secretase proteolytic activity (De Strooper et al., 1998; Vassar et al., 1999; Wolfe et al., 1999) . Imprecise cleavage specificity by g-secretase results in the generation of a range of Ab peptides varying in C-terminal length from 37 up to 46 amino acids (Wiltfang et al., 2002; Lewczuk et al., 2003; Maddalena et al., 2004) although the majority of this pool is composed of Ab40 and Ab42 (Suzuki et al., 1994; Scheuner et al., 1996) . It is now thought that the Ab variation pattern in the brains of patients with Alzheimer's disease is reflected by a general elongation of the Ab peptides through a modulated g-secretase activity (Wiltfang et al., 2002; Lewczuk et al., 2003; Bentahir et al., 2006) . Familial mutations in the gene encoding for the independent composites of the g-secretase complex all induce the formation of longer Ab peptides, which appear to be directly involved in plaque formation in the brains of Alzheimer's disease patients (Jarrett et al., 1993; Suzuki et al., 1994; Scheuner et al., 1996) . The extra residues in the elongated Ab peptides are hydrophobic thus drastically influencing the solubility and amyloidogenicity of the peptide. To effectively study the impact of Ab on toxicity and to elucidate the structural pathway of aggregation and formation of toxic oligomers, it is crucial to initiate the studies with a well-defined aggregatefree Ab species. It is, however, difficult to deal with Ab peptides precisely for the very reason that makes them interesting: they are poorly soluble and aggregation-prone in aqueous solutions. Proteins that are prone to aggregate under physiologically relevant conditions are usually characterized by high hydrophobicity and/or low net charge (Chiti et al., 2003; DuBay et al., 2004; Fernandez-Escamilla et al., 2004; Linding et al., 2004) . Apart from their tendency to induce pathological conditions and high aggregation propensity, the low solubility of these peptides also results in inherent difficulties in the experimental handling and investigation by biophysical techniques and in cell culture. Nevertheless, high-resolution characterization of these proteins may provide the information required to tackle key questions aiming at therapeutic targeting. In response to these technical difficulties that significantly hamper the research into neurodegenerative diseases, a variety of protocols to aid the solubilization of Ab are available in the literature. However, these procedures often involve the use of extremely alkaline (Fezoui et al., 2000) or acidic solutions (Ward et al., 2000) or rely on the presence of organic solvents (Bitan and Teplow, 2004) , thus introducing biologically incompatible compounds and/or conditions that are toxic to cell cultures. Filtration of freshly prepared Ab samples is also frequently used to remove pre-existing aggregates, but often leads to significantly reduced recovery of soluble Ab material (Bernstein et al., 2005) . It is therefore essential to develop a robust and reproducible preparation protocol that allows the solubilization of these peptides under biocompatible buffer conditions.
Here, we describe a new and validated procedure to solubilize the amyloid b-peptide that circumvents the abovementioned problems and allows us to obtain appreciable quantities of virtually aggregate-free material. The method relies on the use of a sequential solubilization procedure with organic solvents, followed by the complete removal of these chemicals to provide a non-toxic environment that is suitable for biophysical characterization. We validated the procedure by demonstrating complete solubilization of the peptide and providing evidence that all chemicals involved are effectively removed from the peptide solution without introducing oxidation of the peptide. By using Thioflavin T fluorescence (Tht) assays and cell culture studies, we show that the resulting solutions exert highly reproducible aggregation kinetics and toxicities. We conclude that our procedure provides monomeric Ab preparations in a cell-biology-compatible environment, and is suitable for biophysical characterization. 
Materials and methods

Reagents
Preparation of Ab peptide solutions
Various ratios of Ab42:Ab40 were prepared starting from material previously stored in a 2208C freezer. The vials containing 0.5 mg Ab-HFIP films were allowed to defrost at room temperature ( 258C) for 10 min. A quantity of 0.5 mg Ab40 or Ab42 was dissolved in 500 ml hexafluoroisopropanol (HFIP). The sample was mixed vigorously using a vortex for 1 min and visually inspected for efficient solubilization. To prepare Ab42:Ab40 ratios, a gas tight syringe was used to add together specific volumes of Ab40 in HFIP and Ab42 in HFIP to obtain a defined ratio of Ab42:Ab40 followed by mixing using a vortex for 1 min. The preparation of specific ratios is further reported by Kuperstein et al. (2010) . The HFIP was evaporated using a gentle stream of oxygen-free nitrogen gas and, alternatively, argon gas can be used. Based on an HFIP volume of 500 ml in each vial prior to drying with nitrogen gas, the peptide/HFIP films were redissolved in 500 ml dimethyl sulfoxide (DMSO). Samples were mixed using a vortex for 1 min and visually inspected for efficient solubilization. Immediately thereafter, the Ab peptide solutions were separated from the DMSO by means of a desalting column (HiTrap TM Desalting column (cat. 17-1408-01), GE Healthcare) that was pre-equilibrated with 25 ml 50 mM Tris-HCl, 1 mM EDTA buffer, pH 7.4. Other buffer systems, including phosphate-buffered saline can also be used. The 500 ml sample was applied to the column using a 1 ml syringe followed by additional injection of 1 ml buffer, the flow-through was discarded. Subsequently, the peptide was eluted from the column by the additional injection of 1 ml buffer. Typically, the first 500 ml flow-through contained 100-120 mM peptide and the second 500 ml contained lower Ab concentrations ( 40-50 mM), which results in a yield of original Ab peptide of 80% based on Bradford determination of the peptide concentration. The Ab-containing samples were collected in pre-cooled lowadhesion resin-coated polypropylene centrifuge tubes (Bioplastics, cat. B74030). After concentration measurement using the Bradford assay for protein determination (Bradford, 1976) , both fractions were combined to yield the required concentration of Ab. Samples were kept on ice directly on elution and further experiments were proceeded with within 20 min after elution from the desalting column.
Oligomerization and fibrillization of Ab
Oligomer-enriched fractions (1.5 -2 h incubation) or amyloid fibrils (.1 week incubation) of Ab were prepared by incubation of 50-100 mM Ab at 258C under quiescent conditions in 50 mM Tris-HCl, 1 mM EDTA, pH 7.4 using low-adhesion resin-coated polypropylene centrifuge tubes.
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)
Non-reducing SDS-PAGE was performed by incubating 10 ml Ab-containing solution in 15 ml Novex Tris-Glycine SDS sample buffer. Samples were then loaded onto a 10-20% Tricine gel (Invitrogen) and the gel was run at 170 V for 40 min followed by staining with Imperial Protein Stain (Pierce).
Thioflavin T (Tht) fluorescence
Aggregate-free Ab42 solutions at a concentration of 50 mM were prepared as described above by further dilution using 50 mM Tris-HCl, 1 mM EDTA containing buffer and a final concentration of 12 mM Tht. In order to evaluate the effect of DMSO on the aggregation kinetics, various concentrations of DMSO (1 -10%) were added to the elution buffer of Ab. In order to validate the effectiveness of the proposed threestep solubilization procedure, Ab42 was also directly dissolved into buffer without organic solvent treatment. The fibrillization kinetics of Ab were monitored in situ using a Fluostar OPTIMA fluorescence plate reader at an excitation wavelength of 440 nm and an emission wavelength of 480 nm. Fluorescence readings were recorded every 10 min for a period of 7 h. Measurements were performed in triplicate, the recorded values were averaged and standard deviations were calculated. Background measurements included buffer or buffer containing DMSO and 12 mM Tht.
Transmission electron microscopy (TEM)
Aliquots (5 ml) of the Ab preparation were adsorbed to carboncoated FormVar film on 400-mesh copper grids (Plano GmbH, Germany) for 1 min. The grids were blotted, washed twice in droplets of Milli-Q water and stained with 1% (wt/vol) uranyl acetate. Samples were studied with a JEOL JEM-1400 microscope at 80 kV (JEOL Ltd, Japan).
Fourier transform infraRed spectroscopy (FT-IR)
An aggregate-free Ab42 solution was prepared as described in the 'Preparation of Ab peptide solutions'. The Ab concentration was adjusted to 100 mM by dilution using 50 mM Tris-HCl, 1 mM EDTA containing buffer. Spectra of Ab42 were recorded directly on elution from the column and after 24 h incubation at 258C under quiescent conditions. To evaluate the contribution of organic solvent components to the FT-IR spectrum, 1% DMSO or 1% HFIP were directly dissolved into 50 mM Tris-HCl, 1 mM EDTA containing buffer. Buffer was used to record a blank signal. The InfraRed spectra were recorded using a Bruker Tensor 27 infrared spectrophotometer (Bruker Optik GmbH, Ettlingen, Germany) equipped with a Bio-ATR II accessory. Spectra were recorded at a spectral resolution of 4 cm 21 and 120 accumulations were performed per measurement at a wavenumber range from 900 to 3500 cm
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. Analysis of the spectra involved blank (buffer) and baseline subtraction from the obtained spectra and rescaling in a wavenumber range from 900 to 1800 cm 21 .
Electrospray-ionization mass spectrometry (ESI-MS)
Ab42 was prepared as described in the 'Preparation of Ab peptide solutions', but the column elution step was disregarded. The concentrated Ab42 solution in DMSO was diluted 100Â in acetonitrile:water (1:1) containing 1% acetic acid to a final concentration of 2 mM Ab. Positive-ion mass spectra were recorded on an orthogonal acceleration quadrupole time-of-flight mass spectrometer (Q-Tof-2, Micromass, Manchester, UK) equipped with a standard electrospray probe (Z-spray) and controlled by a datasystem running MassLynx 3.4 (Micromass, Manchester, UK) and cone voltage was set to 30 V, capillary voltage was 3 kV. Spectra were recorded from m/z 600 to m/z 1600. Scan time was set to 4.9 s with an interscan time of 0.1 s. At least 10 spectra were acquired and averaged. Deconvolution was performed using the MaxEnt algorithm included in the software.
Nuclear magnetic resonance spectroscopy (NMR)
Uniformly 15 N-labeled Ab40 and Ab42 peptides were treated as described above using 1 ml HFIP and 1 ml DMSO. Peptide concentrations were adjusted to 60 mM for Ab42 and 100 mM for Ab40 with 50 mM Tris-HCl, 1 mM EDTA ( pH 7.4) buffer and the samples contained 10% (vol/vol) H-TOCSY experiments. Spectra were processed using NMRPipe/NMRDraw (Delaglio et al., 1995) and analyzed by XEASY/CARA software (Bartels et al., 1995) . (Invitrogen, cat. 15140-122) . The resuspended cells were plated at a volume of 100 ml and a cell density of 20 000 cells/well in a 96-well plate (BD Falcon, cat. 353072). The plated cells were incubated for 48 h at 378C at 5% CO 2 . Ab40 and Ab42 oligomer-enriched fractions were prepared at a concentration of 100 mM as described under section 'Oligomerization and fibrillization of Ab' and incubation for 1.5 h under quiescent conditions at 258C. After incubation, the Ab was diluted to final concentrations of 1 -50 mM in buffer and then diluted 1:1 with pre-
Cell viability in neuroblastoma cells
15 mM HEPES (Gibco, cat. 11039), containing 1% (vol/vol) penicillin/streptomycin (Invitrogen, cat. 15140-122). The Ab or medium as a control was added at a volume of 100 ml in medium to each well and left to incubate for 48 h. After 48 h, 10 ml Cell Titer-Blue w Cell Viability Assay (Promega, cat. G8080) compound was added to each well and incubated for 4-6 h at 378C to allow viable cells to convert resazurin into resorufin. Fluorescence intensity of resorufin was measured on a 96-well plate reader (BMG Labtech, Fluostar Optima) at an excitation wavelength of 544 nm and an emission wavelength of 590 nm. Measurements were performed in three independent experiments and statistical analysis was performed to calculate average values and standard deviations.
Results and discussion
Overview of the protocol and comparison with other methods
The proposed protocol provides for a method to dissolve amyloid beta (Ab) peptide via a rapid three-step procedure. Dissolving recombinant produced Ab42 directly into buffer shows that a Tht curve to follow the kinetic aspects of the aggregation curve lacks the typical sigmoidal shape commonly observed for aggregating peptides and proteins (Fig. 1a) . No lag phase is apparent and also the Tht fluorescence intensity is already increased on starting the assay, both indicative for the presence of pre-formed seeds or aggregates in the solution. FT-IR is used for a wide range of applications and also has shown its applicability in the field of protein conformation determination (Miyazawa and Blout, 1961) . Figure 1b shows that Ab42 that has been prepared using the proposed three-step dissolving procedure is intrinsically unstructured directly after solubilization in aqueous solution, characterized by a broad peak centered around 1654 cm
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, but assumes a b-sheet aggregate fold ( peak at 1627 cm
) on incubation for 24 h. Figure 1c shows that directly in buffer dissolved Ab42 already exerts a high degree of b-sheet structure, while monomeric dissolved Ab is an intrinsically disordered peptide. These results underline the necessity to develop an alternative procedure to dissolve Ab.
We first exploited the structure-promoting properties of HFIP. From a number of tested alcohols, HFIP was shown to most effectively denature the model protein b-lactoglobulin Validated solubilization procedure for Abeta and to induce a non-native a-helix conformation (Hirota et al., 1997) . Dilute solutions of HFIP (1 -4%) promote fibril formation of the islet amyloid polypeptide (Padrick and Miranker, 2002) but concentrated HFIP solutions have been shown to actively remove pre-formed aggregate seeds from solutions containing amyloidogenic proteins (Buck, 1998; Zagorski et al., 1999; Nichols et al., 2005) . Later studies confirmed similar observations for Ab (Nichols et al., 2005) . HFIP owes its activity due to its high degree of fluorination and induces helical formation (Hirota-Nakaoka et al., 2003; Tomaselli et al., 2006). Even though HFIP has been shown to dissociate fibrils, b2-microglobulin aggregates can resist the application of this solvent (Hirota-Nakaoka et al., 2003) . The insufficient ability of HFIP to completely dissociate amyloid fibrils has been ascribed to its non-polar character that weakens hydrophobic interactions but cannot dissolve rigid fibrils (Hirota-Nakaoka et al., 2003) . Therefore, in the presented procedure HFIP solubilization is followed by DMSO, as this polar compound has been shown to completely dissociate amyloid fibrils based on its ability to destruct a hydrogen bond network (Kosower, 1958) . HFIP can be removed using oxygen-free nitrogen gas or, alternatively, argon gas as methionine-35 of the Ab peptide is susceptible to oxidation (Butterfield and Bush, 2004) . A molecular dynamics simulation of the effects of DMSO on the structure and function of subtilisin confirmed that DMSO acts as a highly effective hydrogen bond acceptor and, hence, can strip away water from the protein surface (Zheng and Ornstein, 1996) . Many published methods to solubilize Ab suggest preparation of concentrated Ab stock solutions in DMSO followed by a 10-to 100-fold dilution in buffer to induce aggregation. However, as a result of the effect of DSMO on the hydrogen network of proteins, the kinetics and mechanism of the aggregation of Ab are adversely affected by the presence of small ( 5%) concentrations of DMSO (Fig. 2, and Shen and Murphy, 1995) in a nonphysiologically relevant manner. We therefore apply a column-exchange step to remove all traces of DMSO. Other published methods often employ the effects of HCl and NaOH to aid Ab solubility at a pH far removed from its isoelectric point ( pH 5.3). In order to adjust the pH of the solution to approach more physiologically relevant pH values from an acidic pH requires transition through the isoelectric point at which the peptide is most prone to aggregate. Also the addition of these pH-affecting compounds introduces an additional factor that could induce artifacts in the aggregation mechanism of Ab.
Experimental design
The protocol for Ab solubilization that provided best results consists of sequential treatment using HFIP and DMSO followed by exchange of DMSO into buffer using a desalting column (Fig. 3a) . The use of a high concentration ( 100%) of HFIP, a fluorinated alcohol, provides a means of A concentration of 50 mM Ab was either dissolved directly into buffer or solubilized using the proposed three-step procedure. (b) FT-IR spectroscopy of Ab42 dissolved into buffer using the three-step dissolving procedure. Directly on elution off the column the broad FT-IR spectrum is characteristic for an unstructured peptide while after 24 h incubation at a concentration of 100 mM at 258C the intensity at 1627 cm 21 increases characteristic for b-sheet amyloid aggregation. (c) FT-IR spectroscopy of Ab42 dissolved directly into buffer. Directly on solubilization the spectrum is characteristic for a mixture of unfolded peptide and b-sheet aggregation with a main intensity at 1627 cm 21 and a broad shoulder at 1654 cm 21 . After 24 h incubation at a concentration of 100 mM at 258C the intensity at 1627 cm 21 increased slightly and the shoulder at 1654 cm 21 is smaller.
interaction with the backbone and removal of water from the surface. Subsequently, the HFIP is evaporated off by the use of oxygen-free nitrogen gas or argon gas that protects the peptide from oxidative modification. The hydrophobic methyl groups of DMSO have the ability to then interact with hydrophobic side chains of the Ab peptide while the polar S¼O group interacts with water molecules. DMSO is then removed by buffer exchange using a desalting column resulting in Ab virtually free from aggregating seeds in buffer (Fig. 3b) . The electrophoretic analysis of the elution of Ab from the column shows that fractions 2 -5 are enriched with Ab (150 -750 ml). Ab40 elutes as a pure monomeric solution while Ab42 elutes as a primarily monomeric solution containing small quantities of an SDS-resistant species with an apparent molecular weight resembling trimeric Ab. No higher-molecular-weight aggregates were observed. As the presence of small amounts of HFIP and DMSO can modify the aggregation rates of Ab (Nichols et al., 2005, and Fig. 2) , it is important to validate their complete removal. We use FT-IR that provides characteristic and sensitive fingerprints for the presence of trace amounts of HFIP (Czarnik-Matusewicz et al., 2008) or DMSO. FT-IR spectra of the various elution fractions after column elution show that with increasing elution fraction the concentration of DMSO increases (Fig. 3c) . It is also shown that HFIP has been effectively removed during the procedures supported by the lack of characteristic intensity in the FT-IR spectrum between 1300 and 1100 cm
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. A 1% DMSO solution in buffer has two characteristic peaks: at 1011 cm 21 and one at 951 cm
. Plotting the intensity at these two wavelengths against the fraction number shows that only from fraction 9 (1350 ml) up the concentration of DMSO starts to increase (Fig. 3c) . In addition, the absence of a detectable signal at 2.5 p.p.m., which is characteristic of DMSO, in the one-dimensional 1 H NMR spectrum of the Ab preparations, confirms that elution of the first 1 ml of Ab from the column yields DMSO-free Ab (Fig. 3d) . The electrospray ionization mass spectrum shows that Ab42, using the protocol, eluted free of contaminants and without apparent modifications (Fig. 3e) , such as dityrosine-formation that is commonly observed for Ab peptides as a function of oxidation (Yoburn et al., 2003) .
We tested the reproducibility of the behavior of the prepared Ab solutions and their performance in a variety of assays related to aggregate formation or cell viability commonly used to study the effects of Ab. Commonly used Validated solubilization procedure for Abeta assays to study the aggregation of Ab in vitro consist of thioflavin T fluorescence (Hayashi et al., 2004) , electron microscopy (Hayashi et al., 2004; Martins et al., 2008; Nerelius et al., 2009 ) and FT-IR (Martins et al., 2008; Cerf et al., 2009) and the effect of Ab on the toxicity is usually assayed by viability assays on neuroblastoma cells (Chromy et al., 2003; Nerelius et al., 2009) or neuronal cultures (Lambert et al., 1998; Hayashi et al., 2004; Martins et al., 2008) .
Nuclear magnetic resonance NMR analysis shows that Ab40 and Ab42 prepared by our procedure are mainly monomeric species as shown by the sharp resonances in 2D HSQC experiments (Fig. 4) . NMR analysis also assures us that the protocol does not induce oxidation of Met35: oxidation of this residue is known to result in a notable chemical shift that affects several crosspeaks in the HSQC (Hou et al., 2004) . Our spectra of Ab40 and Ab42 are in excellent agreement with literature data reporting NH of Met35 in the reduced state at 8.5 p.p.m. for the 1 H-frequency, while the NH of Met35 of the oxidized state appeared upfield at 8.8 p.p.m. (Fig. 4a and b, and Hou et al., 2004) . This observation is an important point to note because pre-treatment with HFIP might occasionally promote oxidation of the Ab peptide (Hou et al., 2004) .
Thioflavin T fluorescence
Tht fluorescence is a useful probe to assay the aggregation of proteins. The quantum yield for fluorescence of this weakly fluorescent dye increases strongly on complexation with amyloid fibrils (Naiki et al., 1989) . Fig. 5a shows that differences in aggregation rates between the aggregating Ab42 and less aggregation-prone Ab40 can be distinguished using in situ. Tht fluorescence. Reproducibility of the obtained results is an important parameter to evaluate the quality of the developed procedures. Figure 5a shows Tht fluorescence curves obtained for three independent experiments. The standard error between the experiments is 7-10% and the differences between the aggregation rates of Ab40 and Ab42 are therefore significant.
Transmission electron microscopy
We used TEM to characterize fibril morphology of aggregates formed by Ab40 and Ab42 on incubation at a concentration of 100 mM for 24 h at 258C. Amyloidogenic Ab42 (Fig. 5b) forms aggregates characterized by short fibrils which intertwine and appear rigid. Ab40 (Fig. 5c) on the other hand forms long semi-flexible negatively stained fibrils with a characteristic periodic twist that is regularly found in fibrils of other origin, such as insulin (Jiménez et al., 2002) .
Toxicity on SH-SY5Y cells
The toxicity of 1.5 h incubated 100 mM Ab40 and Ab42 preparations was tested using neuroblastoma SH-SY5Y cells plated at a cell density of 20 000 cells/well in serum-deprived medium. To this end, Ab preparations were diluted to various concentrations ranging from 1 to 50 mM in serum-deprived medium and 100 ml was added to each well in 6-fold. After 48 h incubation cells were tested for cell death using Cell Titer-Blue viability assay (Promega). Figure 5d shows that cell viability is Ab concentration dependent and that Ab42 aggregates induce cell death at lower concentrations (from 7.5 mM) compared with Ab40 aggregates (from 30 mM). The results in Fig. 5d are obtained from three independent (Hou et al., 2004). experiments and the standard error is maximum 12% (for 30 mM Ab40) but in most cases .5%.
Conclusions
A robust and validated three-step procedure is presented to prepare biocompatible virtually aggregate-free solutions with an efficient recovery of amyloidogenic Ab42 implicated in Alzheimer's disease. The procedure involves the sequential use of HFIP, DMSO and a column exchange step. While the use of organic solvents also allows the reliable preparation of biologically relevant quantities of Ab42 and Ab40 and their mixtures, the incorporation of a desalting column in the solubilization procedure makes it possible to obtain the Ab peptide in any desirably buffer system. The resulting Ab preparation shows highly reproducible biophysical and cell biological behavior. The use of this protocol may be extended to the solubilization of other highly amphipathic or hydrophobic polypeptides. Validated solubilization procedure for Abeta
